This is an old revision of this page, as edited by 156.57.123.130(talk) at 03:50, 9 February 2025(Added "inhibition"). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.Revision as of 03:50, 9 February 2025 by 156.57.123.130(talk)(Added "inhibition")
As cancer appeared more frequently in patients treated with simvastatin-ezetimibe combination therapy in one clinical trial,[11] it had been hypothesized that NPC1L1 inhibition by ezetimibe might be associated with an increased cancer risk.[12] However, a meta-analysis of ezetimibe clinical data showed no increase in the risk of cancer from treatment with ezetimibe.[13]
^Savarese G, De Ferrari GM, Rosano GM, Perrone-Filardi P (December 2015). "Safety and efficacy of ezetimibe: A meta-analysis". International Journal of Cardiology. 201: 247–52. doi:10.1016/j.ijcard.2015.08.103. PMID26301648.
Overview of all the structural information available in the PDB for UniProt: Q9UHC9 (Human NPC1-like intracellular cholesterol transporter 1) at the PDBe-KB.